RedHill's antibiotic Talicia edges closer to approval, after second successful Phase III study
As one of the few companies focusing on tackling the burgeoning threat of superbugs, Israel’s RedHill Biopharma $RDHL is making strides. On Monday, it said …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
